Ginseng vs. fatigue: major trial tests natural remedy for cancer patients
NCT ID NCT06395441
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase III trial tests whether American ginseng can reduce fatigue in 160 cancer patients. Fatigue is a common and tough side effect of cancer and its treatment. Participants will take either ginseng or a placebo, and researchers will measure changes in fatigue levels over time.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- American ginseng (dietary supplement)
- What this could lead to
- If it works, this could provide a natural option to ease cancer-related fatigue, improving quality of life for many patients.
- What could go wrong
- This is a large Phase III trial, but fatigue is subjective and the placebo effect is strong. Ginseng may not outperform placebo, and results may not apply to all cancer types.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
About 160 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2024
- Expected to finish
-
Nov 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥ 18 years * Has received or is receiving treatment for a solid-organ malignancy (not hematologic) * History of cancer-related fatigue as defined by an average score ≥ 4 over the past 30 days on the numeric analogue scale. Patients can answer questions orally rather than completing worksheet * Baseline control of insomnia: Insomnia ≤ 4 on Linear Analogue Scale. Patients can answer questions orally rather than completing worksheet * Baseline control of pain: Pain ≤ 4 on Linear Analogue Scale. Patients can answer questions orally rather than completing worksheet * Life expectancy ≥ 6 months * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2 * Hemoglobin ≥ 10.0 g/dL (patients must not have been transfused in the preceding 90 days to meet this criterion) (≤ 180 days prior to registration) * Alanine aminotransferase (ALT) or aspartate transaminase (AST) ≤ 3 x upper limit normal (ULN) (≤ 180 days prior to registration) * Creatinine ≤ 1.5 x ULN (≤ 180 days prior to registration) * No clinical suspicion of hypothyroidism within 180 days prior to registration \[if clinical suspicion of hypothyroidism exists, a documented thyroid stimulating hormone (TSH) \< 5 milli-international units per liter (mIU/L) is required\] * Negative pregnancy test done ≤ 7 days prior to registration, for persons of childbearing potential only * Ability to complete questionnaire(s) by themselves or with assistance * Provide informed consent Exclusion Criteria: * Any known hypersensitivity to ginseng * Currently using any other pharmacologic agents to specifically treat fatigue including psychostimulants or antidepressants. Note: Antidepressants used to treat items other than fatigue (such as hot flashes or depression) are allowed if the patient has been on a stable dose for ≥ 30 days and plan to continue such for 8 weeks. Exercise is allowed * Psychiatric disorder such as poorly controlled depression, manic depressive disorder, obsessive compulsive disorder, or schizophrenia (defined per medical history) * Use of erythropoietic agents ≤ 6 months * Uncontrolled hypertension on more than three occasions (diastolic blood pressure ≥ 100, systolic ≥ 160) measured ≤ 180 days prior to randomization * Surgery that required general anesthetic ≤ 30 days prior to randomization * Malnutrition, active infection, severe depression, or significant pulmonary disease and cardiovascular disease (as determined by the attending clinician), as they could impact fatigue * Use of any over the counter herbal/dietary supplement marketed for fatigue or energy (for example, products containing any type of ginseng, Rhodiola rosea, guarana, or anything called an "adaptogen") * Currently using an antidiabetic drug, warfarin or monamine oxide inhibitor * Treating provider anticipates a change to the anti-cancer treatment program in the next 8 weeks (i.e., the intervention period)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hematopoietic and lymphatic system neoplasm are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The study's own enquiry address
This study publishes an address for enquiries. See it below .
-
The places running it
14 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Essentia Health Cancer Center
RECRUITINGDuluth, Minnesota, 55805, United States
Contact Email: •••••@•••••
-
Essentia Health Deer River Clinic
RECRUITINGDeer River, Minnesota, 56636, United States
Contact Email: •••••@•••••
-
Essentia Health Fosston
RECRUITINGFosston, Minnesota, 56542, United States
Contact Email: •••••@•••••
-
Essentia Health Hibbing Clinic
RECRUITINGHibbing, Minnesota, 55746, United States
Contact Email: •••••@•••••
-
Essentia Health Saint Joseph's Medical Center
RECRUITINGBrainerd, Minnesota, 56401, United States
Contact Email: •••••@•••••
-
Essentia Health Sandstone
RECRUITINGSandstone, Minnesota, 55072, United States
Contact Email: •••••@•••••
-
Essentia Health St. Mary's Detroit Lakes Clinic
RECRUITINGDetroit Lakes, Minnesota, 56501, United States
Contact Email: •••••@•••••
-
Essentia Health Virginia Clinic
RECRUITINGVirginia, Minnesota, 55792, United States
Contact Email: •••••@•••••
-
MMCORC CentraCare Monticello Cancer Center
COMPLETEDMonticello, Minnesota, 55362, United States
-
Mayo Clinic Health System in Albert Lea
RECRUITINGAlbert Lea, Minnesota, 56007, United States
Contact Email: •••••@•••••
-
Mayo Clinic Health System-Mankato
RECRUITINGMankato, Minnesota, 56001, United States
Contact Email: •••••@•••••
-
Mayo Clinic in Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact Email: •••••@•••••
-
Sanford Joe Lueken Cancer Center
RECRUITINGBemidji, Minnesota, 56601, United States
Contact Email: •••••@•••••
-
Sanford Thief River Falls Medical Center
RECRUITINGThief River Falls, Minnesota, 56701, United States
Contact Email: •••••@•••••
-
Sanford Worthington Medical Center
RECRUITINGWorthington, Minnesota, 56187, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a vaccine stop GI cancers from returning?
- Can a phone app help childhood cancer survivors keep track of their health?
- Can the way we word cancer research invitations boost participation?
- A chill pill for Chemo's side effects? cooling therapy and a Blood-Flow drug take on nerve pain
- Wearable tech could spot Post-Surgery problems early
- Can an AI chatbot ease the aftermath of cancer?